Cargando…

Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling

Targeted therapy is an effective, rational, and safe approach to solid and hematological tumors treatment. Unfortunately, a significant fraction of patients treated with tyrosine kinase inhibitors (TKI) relapses mainly because of gene amplification, mutations, or other bypass mechanisms. Recently a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceccon, Monica, Mauri, Mario, Massimino, Luca, Giudici, Giovanni, Piazza, Rocco, Gambacorti-Passerini, Carlo, Mologni, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316814/ https://www.ncbi.nlm.nih.gov/pubmed/30545064 http://dx.doi.org/10.3390/cancers10120509

Ejemplares similares

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015)

Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
por: Mologni, Luca, et al.
Publicado: (2012)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization
por: Crespiatico, Ilaria, et al.
Publicado: (2019)

Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma
por: Arosio, Giulia, et al.
Publicado: (2021)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells
por: Magistroni, Vera, et al.
Publicado: (2011)

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
por: Redaelli, Sara, et al.
Publicado: (2015)

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022)

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition
por: Mologni, Luca, et al.
Publicado: (2017)

Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase
por: Mologni, Luca, et al.
Publicado: (2022)

OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes
por: Rocco, Piazza, et al.
Publicado: (2017)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes
por: Piazza, Rocco, et al.
Publicado: (2017)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
por: Sharma, Geeta Geeta, et al.
Publicado: (2018)

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
por: Malighetti, Federica, et al.
Publicado: (2023)

Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia
por: Aroldi, Andrea, et al.
Publicado: (2023)

Correction to “Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase”
por: Mologni, Luca, et al.
Publicado: (2022)

P1235: INVESTIGATION OF THE CO-MUTATIONAL LANDSCAPE OF ALK-POSITIVE ALCL
por: Villa, Matteo, et al.
Publicado: (2023)

CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data
por: Piazza, Rocco, et al.
Publicado: (2013)

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2022)

FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery
por: Piazza, Rocco, et al.
Publicado: (2012)

VERSO: A comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples
por: Ramazzotti, Daniele, et al.
Publicado: (2021)

Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2021)

Dual Kinase Targeting in Leukemia
por: Mologni, Luca, et al.
Publicado: (2021)

Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain
por: Raivola, Juuli, et al.
Publicado: (2018)

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases
por: Spinelli, Roberta, et al.
Publicado: (2013)

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases
por: Spinelli, Roberta, et al.
Publicado: (2014)

P1056: NEXT GENERATION SEQUENCING IDENTIFIES SUBGROUPS OF PATIENTS WITH TRIPLE NEGATIVE/ PRIMARY THROMBOCYTOSIS WITH DIFFERENT CLINICAL OUTCOMES
por: Sangiorgio, Valentina, et al.
Publicado: (2023)

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia
por: Khoury, H J, et al.
Publicado: (2018)

Protein kinases regulate hyperactivated motility of human sperm
por: Wang, Ya-Yan, et al.
Publicado: (2021)

Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2020)

Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients
por: Fontana, Diletta, et al.
Publicado: (2023)

Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B
por: Cipriano, Rocky, et al.
Publicado: (2013)

Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS
por: Wang, Dan, et al.
Publicado: (2019)

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas
por: Rindone, Giovanni, et al.
Publicado: (2022)

Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV
por: Yasmeen, Amber, et al.
Publicado: (2010)

Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Aroldi, Andrea, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r3ufjifj6bsb8muvkjbjcc393q